GENOMED THERAPY COULD REDUCE HELATHCARE COSTS
At GenoMed: David W. Moskowitz Chairman, President & CEO (314) 983-9933
At The Investor Relations Company: Mike Arneth or Brien Gately (847) 296-4200
St. Louis, February 23, 2005 --GenoMed, Inc. (Pink Sheets: GMED) announced today that its top executive, in an appearance before a conference of senior medical officers of health insurance providers and other organizations, said treatment evidence indicates the company's therapy regimen could save millions of dollars in health care costs annually. The savings would result from prevention of the onset of a number of diseases, most notably diabetes, in individuals at risk. It also offers those who already suffer from diabetes or high blood pressure the hope of preventing many of the complications, including kidney failure, amputation, heart disease, nerve damage and blindness.
Speaking before attendees AT a conference on Evidence-Based Medicine for health plans held in Scottsdale, AZ last week, GenoMed CEO and Chief Medical Officer David W. Moskowitz presented data from a number of patients. The data indicated specific ACE Inhibitors in the correct doses can prevent kidney failure in patients with diabetes or high blood pressure.
Commenting on the data presented at the conference, Moskowitz said "The therapeutic benefits we've witnessed among diabetic or hypertensive patients who have been on our patent-pending regimen of ACE inhibitors have been dramatic. In the case of kidney failure, we have actually seen an improvement in kidney function in patients when we have been able to start them on our course of treatment before they have lost 50% of their kidney function. This is the first time that regression of kidney failure has ever been seen."
"While the therapeutic benefits alone make the effort worthwhile, the economic implications of preventing diabetes and its complications are staggering. There are 20 million adults in the US with diabetes, and 60 million more with high blood pressure. Since the late 1980'S, diabetes has led high blood pressure as the top two causes of kidney failure. Data for 2001 indicates the total cost for kidney dialysis was $18 billion or approximately $90,000 for each of the approximately 200,000 patients requiring the treatment. Estimates are that by the year 2010 there will be 300,000 patients requiring dialysis and the cost of treatment will rise to $150,000 per year. We believe if our treatment is employed, many of the patients who might otherwise require dialysis could avoid kidney failure. Individuals and healthcare insurance providers could avoid billions of dollars in costs while at the same time improving the quality of life for hundreds of thousands of Americans," Moskowitz added.
GenoMed offers consultative services to patients and their physicians. The cost of the service, currently $67 per month or $800 per year, is no more than the average American spends on vitamins, according to Moskowitz. He also said the return on investment, particularly in the case of conditions like kidney failure, is dramatic. The treatment is also patient-friendly because patients can maintain their relationship with their primary physician while benefiting from the cutting edge molecular medicine GenoMed has developed, he noted.
Moskowitz said he believes there are a wide variety of additional diseases that can be prevented or treated by GenoMed's approach. These include a variety of common cancers such as pancreatic, breast and lung cancer, Alzheimer's disease, Parkinson's disease, West Nile Virus and others. The company has a number of clinical trials underway.
About GenoMed
GenoMed is leading the clinical revolution which knowledge of disease genes has already made possible. GenoMed is currently marketing its protocols to prevent the need for kidney dialysis due to high blood pressure and diabetes, and to delay the progression of emphysema. The company also conducts basic research to find genes that cause different diseases and clinical research to test protocols that look promising for improving patient outcomes.
. |
